AOD-9604 & CJC-1295 & Ipamorelin vs Retatrutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
AOD-9604 & CJC-1295 & Ipamorelin
A targeted fat loss stack combining AOD-9604 (the fat-burning fragment of HGH) with CJC-1295 and Ipamorelin for comprehensive body recomposition. This blend addresses fat loss directly while supporting lean mass through GH optimization.
Full details →Retatrutide
Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied.
Full details →Side-by-Side Comparison
| Aspect | AOD-9604 & CJC-1295 & Ipamorelin | Retatrutide |
|---|---|---|
| Mechanism | AOD-9604 stimulates lipolysis and inhibits lipogenesis without affecting IGF-1 or blood glucose. CJC-1295 and Ipamorelin provide sustained and pulsatile GH release to support metabolism and lean tissue. The combination targets fat loss through multiple mechanisms while preserving muscle. | Triple receptor activation provides complementary metabolic effects: GLP-1 and GIP reduce appetite and improve insulin sensitivity, while glucagon receptor activation increases energy expenditure and promotes hepatic fat oxidation. |
| Typical Dosage | Typical protocol: AOD-9604 200-400mcg, CJC-1295 100-200mcg, Ipamorelin 100-200mcg daily. Usually administered in the morning fasted or before exercise. | Clinical trials used doses from 1mg to 12mg weekly. Optimal dosing still being determined in ongoing Phase 3 trials. |
| Administration | Subcutaneous injection. Best administered fasted to maximize fat-burning effects. Can be taken as a pre-mixed blend or separate injections. Cycles typically run 8-16 weeks. | Subcutaneous injection once weekly. Currently only available through clinical trials - not yet FDA approved. |
| Side Effects | Mild injection site reactions, headache, nausea. Generally well-tolerated as AOD-9604 lacks many HGH side effects. | Similar GI effects to other incretin-based therapies: nausea, diarrhea, vomiting, constipation. Dose-dependent severity. |
| Best For |
What They Have in Common
Both AOD-9604 & CJC-1295 & Ipamorelin and Retatrutide are commonly used for: